Armata Pharmaceuticals In... (ARMP)
2.05
0.03 (1.74%)
At close: Jan 15, 2025, 2:30 PM
Company Description
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology.
The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is headquartered in Marina del Rey, California.
Armata Pharmaceuticals Inc.
| Country | United States |
| IPO Date | May 20, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Dr. Deborah L. Birx M.D. |
Contact Details
Address: 4503 Glencoe Avenue Marina del Rey, California United States | |
| Website | https://www.armatapharma.com |
Stock Details
| Ticker Symbol | ARMP |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921114 |
| CUSIP Number | 04216R102 |
| ISIN Number | US04216R1023 |
| Employer ID | 91-1549568 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Deborah L. Birx M.D. | Chief Executive Officer & Director |
| David House | Senior Vice President of Finance & Principal Financial Officer |
| Dr. Mina Pastagia M.D., MS | Chief Medical Officer |
| Dr. Pierre Kyme Ph.D. | Chief Business Officer |
| Peter Hubbard | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | 8-K | Current Report |
| Dec 04, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13D/A | [Amend] Filing |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 03, 2024 | 8-K | Current Report |
| Oct 03, 2024 | 4 | Filing |
| Sep 26, 2024 | 8-K | Current Report |